Politiques éditoriales

Publication ethics

Conflicts of interest Declaration of Helsinki Plagiarism and data tampering Redundant submissions and publications Article authorship Advertising

Droits d’auteur et de reproduction
Soumission d’un article
Sélection des articles pour publication
Révision des articles
Libre accès
Indépendance de contenu et décharge de responsabilité


Éthique en matière de publication

Pharmactuel adhère aux bonnes pratiques de publication du Committee on Publication Ethics (COPE), telles que détaillées sur le site Web de l’organisation dans le Code of conduct and best practice guidelines for journal editors .  Pharmactuel est également membre de l'European Association of Science Editors (EASE).

Conflits d’intérêts

Editorial Board
Once a year, the members of the Editorial Board sign a conflict of interest declaration. Associate editors are not involved in the editorial process if they are authors. If it is a manuscript for their column, it is assigned to another associate editor. The participation of the associate editor in the editorial board of Pharmactuel is mentioned in the "conflicts of interest" section of the manuscripts of which he is the author.

Pharmactuel was inspired by the International Committee of Medical Journal Editors (ICMJE) form for the disclosure of interests by authors. The latter provides for the declaration of any real or potential conflict of interest as well as any source of funding related to the work leading to the submission of the manuscript for publication. The information disclosed by each author will be mentioned in the article at the time of its publication. The Disclosure of Potential Conflicts of Interest and Copyright License for Publication of an Article Submitted to Pharmactuel form can be downloaded from the Disclosure of Conflicts of Interest from Funding Sources section under Information for Authors.

The editorial board reserves the right to refuse a manuscript if there is any doubt as to the scientific value of its content due to a conflict of interest.

Anyone invited or engaged to revise an article must waive or withdraw if they deem to be in the presence of a real or potential conflict of interest.

Declaration of Helsinki

Articles resulting from a research project must comply with the ethical recommendations of the Declaration of Helsinki . Research projects must first be submitted, if they so require, either to an advisory committee for the protection of persons participating in biomedical research, or to an ethics committee.

Plagiarism and falsification of data

The author must ensure that the data presented in the manuscript submitted to Pharmactuel are original and accurate, and free from any form of plagiarism.

The Pharmactuel editorial board adheres to the recommendations made on plagiarism and data falsification by the Committee on Publication Ethics (COPE) in its document entitled Code of conduct and best practice guidelines for journal editors . The editorial board also undertakes to follow the approach recommended by this organization in the event of suspicion of plagiarism or falsified data, as illustrated in the organization charts published on their website. It reserves the right to reject a submission, or to publish an erratum or a notice of withdrawal if evidence of plagiarism, falsification or data errors is brought to its attention after the publication of an article.

Redundant submissions and publications

The author should ensure that his manuscript is not submitted to several journals simultaneously. He must also ensure that the results of the work presented in the manuscript submitted to Pharmactuel have not been presented in whole or in part in another manuscript or another publication.

The Pharmactuel editorial board adheres to the recommendations made by the Committee on Publication Ethics (COPE) , with regard to redundant publications and the slurping of research results. The editorial committee undertakes to follow the process detailed in the organization chart published by COPE, entitled  What to do if you suspect a redundant (or double) publication .

The editorial board reserves the right to ask authors to provide previous articles on the same subject, in order to avoid any duplication of publication. It also reserves the right to reject a submission, or to publish a redundant publication statement or a withdrawal notice in the event of redundant publication proven.

Authorship of an article

The Pharmactuel Editorial Board adheres to the recommendations of the International Committee of Medical Journal Editors (ICMJE) with respect to authorship of articles. In order for a person to be legitimately recognized as an author of an article, four conditions must be met:

  1. The person must make a substantial contribution to the design of the manuscript, to the acquisition of the data, to the analysis or to the interpretation of the results;
  2. The person must participate in the draft of the manuscript or contribute significantly to the revision of its intellectual content;
  3. The person must approve the final version of the manuscript;
  4. The individual accepts responsibility for all aspects of the published work ensuring that questions relating to the accuracy and integrity of the content of the manuscript have been raised and satisfactorily resolved.

All persons designated as the author of a manuscript submitted to Pharmactuel must meet these four conditions. In addition, all persons qualifying as authors must be identified as such in the manuscript. The manuscript must list all the authors in descending order of contribution, the author who contributed the most to the drafting of the manuscript appearing first.

Students cannot submit a manuscript to Pharmactuel as sole authors. A pharmacist, researcher or other health professional who participated in the writing of the article must act as co-author.

People who contributed to the manuscript but do not meet all of the ICMJE criteria should be mentioned at the end of the article in the Acknowledgments section. All persons mentioned in this section must provide their written consent before publication of the manuscript.

When requesting the addition or removal of an author after publication of an article, clear explanations regarding this change must be provided and an agreement signed by all authors of the manuscript must be sent to the Editorial Board.


Advertisements submitted for publication in Pharmactuel must be relevant to the practice of pharmacy and approved by the editor-in-chief or his delegate, before publication.

Seuls les membres du comité de rédaction de la revue ont droit de regard sur son contenu scientifique. Aucune information sur le contenu de la revue n’est transmise au représentant publicitaire de Pharmactuel. Ce dernier ne peut exercer quelque influence que ce soit sur le contenu de la revue à publier.

La loi canadienne présentement en vigueur interdit la publicité directe de médicaments d'ordonnance au grand public. En conséquence, et puisque Pharmactuel est disponible uniquement en version électronique libre d’accès, aucun matériel publicitaire de nature à enfreindre la loi canadienne ne sera accepté pour publication dans Pharmactuel. Néanmoins, chaque annonceur est responsable de respecter les dispositions de la loi quant au contenu des annonces soumises pour publication à Pharmactuel. Ni Pharmactuel ni l’Association des pharmaciens des établissements de santé du Québec ne peuvent être tenus responsables du contenu publicitaire de la revue.

Advertisements published in the electronic flip-page journal version are placed on separate pages from the scientific content. No advertisement is inserted between two pages of the same article. The announcements published on the Pharmactuel website are not associated with any specific article. Advertisements for tobacco products or alcoholic beverages as well as job offers are rejected out of hand.

Copyright and reproduction rights

All of Pharmactuel's content is protected by copyright and by Quebec, Canadian and foreign intellectual property laws. The content or the copyright in the content belongs to the Association des pharmaciens des establishments de santé du Québec (APES).

By submitting their literary works for publication in Pharmactuel and by granting free of charge the Disclosure of potential conflicts of interest and copyright license for publication of an article submitted to Pharmactuel submitted to Pharmactuel (the License), the authors allow to the APES to exploit, on an exclusive and unrestricted basis, all the copyright, in particular the reproduction right, which they hold on the said literary works.

In accordance with the terms of the License, if the submitted manuscript is not published in the four issues of Pharmactuel following the date of acceptance of the manuscript, the License granted free of charge lapses.

As soon as the manuscript is published, it is therefore forbidden for any person, including the authors, to reproduce, in whole or in part and by any means whatsoever, the texts, figures, tables and illustrations contained in Pharmactuel.

Reproduction may, however, be the subject of a written request to APES. A reproduction authorization form can be obtained by contacting the Pharmactuel coordinator at coordonnateur@pharmactuel.com .

Submission of an article

The author must upload his manuscript and related documents to the Pharmactuel site. The procedure for submitting an article is detailed in the Submission of an article section under Information for authors.

Selection of articles for publication

In order to be considered, manuscripts submitted to Pharmactuel must be original, fit into one of the journal's columns and never have been published before. The author also undertakes to respect the recommendations to the authors, failing which the submitted article will be returned to him.

All articles submitted for publication are pre-selected by the editorial board. The articles eliminated during this first selection are immediately rejected. At this stage, for example, a manuscript may be refused if its subject matter is not intended for the journal's readership.

Review of articles

Manuscripts submitted for the Unit's Critical Review of the Scientific Literature, Research, Pharmacotherapy, and Clinical Case Reviews are peer reviewed. The content of articles submitted for chronicles of a clinical or administrative nature is edited by the associate editor or associate editor responsible for the column. If necessary, these articles are submitted to an external reviewer.

Reviewers ensure that the article meets the author's recommendations , that it is suitable for the readership, and that the content is scientifically sound. The anonymity of authors and reviewers is preserved throughout the review process. The review process is detailed in the Information for Reviewers section .

Reader comments

Readers wishing to comment on a manuscript can send them to the editor-in-chief of Pharmactuel by email (redaction@pharmactuel.com). Constructive and ethical comments could be published in the “Letter to Editor” column.

Corrections and withdrawal following publication

When a manuscript is already published and a need for correction or a major error is discovered, the publication of an erratum is made as quickly as possible. A new version of the article is published on the journal's website. In the event of discovery of major errors invalidating the results and conclusions contained in the manuscript, a retraction thereof is made, and it is permanently removed from the journal's website. On the other hand, a trace of the publication and of the withdrawal will be kept on the site, including an explanatory text and the complete citation of the original reference. A copy of the article will be kept in the internal archives of the journal. A withdrawal is also made in the event of discovery of a duplication of publication.

Scientific misconduct

Readers suspecting a scientific misconduct problem with a manuscript can contact the editor-in-chief of Pharmactuel by email (redaction@pharmactuel.com). The guidelines proposed by COPE regarding scientific misconduct will be followed in the event that this practice is suspected (https://publicationethics.org/).


Pharmactuel is published online four times a year, in March, June, September and December.

Free access

The electronic version of Pharmactuel is available free of charge at: www.pharmactuel.com .

As a result, researchers who publish in the journal Pharmactuel meet their obligation to make the article resulting from their research accessible free of charge, as provided for in the open access policy of the three federal granting agencies (Natural Sciences and Engineering Research Council of Canada, Social Sciences and Humanities Research Council and Canadian Institutes of Health Research). The transfer of articles published in Pharmactuel in any institutional repository, whether university or not, is prohibited.

Independence of content and disclaimer

Although the Association des pharmaciens des establishments de santé du Québec (APES) financially supports the publication of Pharmactuel, only the members of the journal's editorial board have the right to review its scientific content. The points of view expressed in the articles are those of their authors and do not necessarily represent the official position of the EPAS Consequently, the EPAS can in no way be held responsible for the conclusions drawn by the authors and, more broadly, of content published in the journal.

Publication costs

The publication costs are fully covered by the APES, the authors have no amount to pay for the publication of their manuscripts.


Authors submitting case reports should ensure that any information that may reveal the identity of those whose cases are reported is not published. Patient consent must be obtained in order to publish a case. A statutory declaration signed by the authors and attesting that such authorization has been obtained is required for the publication of manuscripts relating to one or more patients (see the information section for the authors). Case reports from deceased patients will not be accepted for publication. In addition, no photo identifying individuals will be published.

The members of the Pharmactuel editorial board take all necessary measures to preserve the confidentiality of the manuscripts being submitted to the journal throughout the editorial process.


Revision on February 26, 2021